Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Take Strict Action on Bayer after Xarelto Survey Probe
July 19, 2017
- MHLW Panel Agrees to Compile Guidelines to Address Polypharmacy in the Elderly
July 18, 2017
- Gov’t Establishing System to Quickly Provide Unapproved Drugs to Developing Countries, Learning from Inadequate Response to Request for Avigan
July 18, 2017
- Pfizer’s Breast Cancer Med Palbociclib Up for MHLW Panel Review on July 27
July 14, 2017
- Drug Price Cut Only Way to Eke Out FY2018 Funding, though Pharmas Important: Top MD Bureaucrat
July 14, 2017
- MHLW Presents Draft Survey Sheet for “Willing-to-Pay” Costs in “CEA” Scheme: Chuikyo
July 13, 2017
- Chuikyo Starts Debate on Interim Report on CEA, Industry Hearings Slated for Next Meeting
July 13, 2017
- Alminoprofen Reclassified as Class 1 OTC Drug: MHLW
July 13, 2017
- Osaka Prefecture to Conduct Surprise Onsite Inspections of API Manufacturing Facilities in Wake of Acetaminophen Scandal
July 13, 2017
- Retired Vice Minister Happy to See Stage Set for Timely Price Revisions
July 12, 2017
- MHLW to Announce Data Required for Conditional Early Approval
July 12, 2017
- Further Transformation beyond Pricing Overhaul Inevitable: Outgoing MHLW Economic Affairs Chief
July 10, 2017
- Applications for Partial Modification to Suffice to Change Manufacturing Processes for Biopharmaceuticals: MHLW Notification
July 7, 2017
- MHLW to Enhance Awareness about Tougher Controls on Private Importing of Drugs by Doctors
July 7, 2017
- MHLW Floats Standard Processing Time for Cost-Effective Assessments: Chuikyo
July 6, 2017
- Chuikyo Reps Trade Barbs over Timing of Post-“CEA” Price Adjustments
July 6, 2017
- Drugs Containing Codeine to Be Contraindicated in Children Younger than 12: MHLW Notifications
July 6, 2017
- Suzuki Tapped for Newly Created Medical Commissioner Post: MHLW Personnel Reshuffle
July 5, 2017
- Add Sclerosing Cholangitis to ADR List in Opdivo Label: MHLW
July 5, 2017
- MHLW OKs Spinraza, Tenelia-Canaglu Combo, and More
July 4, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…